Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124731913 | 12473191 | 3 | F | 20160725 | 20160616 | 20160727 | EXP | US-PFIZER INC-2016297514 | PFIZER | WALLACE, K. L.. SUBTHERAPEUTIC VORICONAZOLE CONCENTRATIONS ASSOCIATED WITH CONCOMITANT DEXAMETHASONE: CASE REPORT AND REVIEW OF THE LITERATURE.. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016 | 84.00 | YR | M | Y | 60.00000 | KG | 20160727 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124731913 | 12473191 | 1 | PS | VORICONAZOLE. | VORICONAZOLE | 1 | 250 MG, 2X/DAY (4 MG/KG,Q12H FOR ONE WEEK) | 21266 | 250 | MG | BID | ||||||||
| 124731913 | 12473191 | 2 | I | VORICONAZOLE. | VORICONAZOLE | 1 | 200 MG, 2X/DAY (Q12H) | 21266 | 200 | MG | BID | ||||||||
| 124731913 | 12473191 | 3 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 250 MG, 2X/DAY(Q12H) | 21266 | 250 | MG | BID | |||||||
| 124731913 | 12473191 | 4 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 300 MG, 2X/DAY (Q12H) | 21266 | 300 | MG | BID | |||||||
| 124731913 | 12473191 | 5 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 400 MG, 2X/DAY 6 MG/KG,EVERY 12 HOURS (Q12H) X 2 DOSES | U | 21267 | 400 | MG | POWDER FOR SOLUTION FOR INFUSION | BID | |||||
| 124731913 | 12473191 | 6 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 300 MG, 2X/DAY (Q12H) | U | 21267 | 300 | MG | POWDER FOR SOLUTION FOR INFUSION | BID | |||||
| 124731913 | 12473191 | 7 | I | VORICONAZOLE. | VORICONAZOLE | 1 | U | 21267 | POWDER FOR SOLUTION FOR INFUSION | ||||||||||
| 124731913 | 12473191 | 8 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, 3X/DAY (EVERY 8 HOURS (Q8H) | 0 | 4 | MG | TID | |||||||
| 124731913 | 12473191 | 9 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, 3X/DAY (Q8H) | 0 | 4 | MG | TID | |||||||
| 124731913 | 12473191 | 10 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 3 MG, 3X/DAY (Q8H) | 0 | 3 | MG | TID | |||||||
| 124731913 | 12473191 | 11 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | 2 MG, 3X/DAY (Q8H) | 0 | 2 | MG | TID | ||||||||
| 124731913 | 12473191 | 12 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | 1 MG, 3X/DAY (Q8H) | 0 | 1 | MG | TID | ||||||||
| 124731913 | 12473191 | 13 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | 0.5 MG, 3X/DAY (Q8H) | 0 | .5 | MG | TID | ||||||||
| 124731913 | 12473191 | 14 | C | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 124731913 | 12473191 | 15 | C | VANCOMYCIN | VANCOMYCIN | 1 | UNK | 0 | |||||||||||
| 124731913 | 12473191 | 16 | C | METRONIDAZOLE. | METRONIDAZOLE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124731913 | 12473191 | 1 | Antifungal treatment |
| 124731913 | 12473191 | 2 | Cerebral fungal infection |
| 124731913 | 12473191 | 3 | Phaehyphomycosis |
| 124731913 | 12473191 | 5 | Cerebral fungal infection |
| 124731913 | 12473191 | 6 | Antifungal treatment |
| 124731913 | 12473191 | 7 | Phaehyphomycosis |
| 124731913 | 12473191 | 8 | Brain oedema |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124731913 | 12473191 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124731913 | 12473191 | Drug interaction | |
| 124731913 | 12473191 | Drug level below therapeutic | |
| 124731913 | 12473191 | Product use issue | |
| 124731913 | 12473191 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |